Dicerna Pharmaceuticals’ Co-founders Publish Studies Describing Novel Approaches to Maximizing Dicer-Substrate Small Interfering RNAs (DsiRNAs)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology™, today announced key studies highlighting the therapeutic potential for Dicer-substrate small interfering RNAs (DsiRNAs).